These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38940622)

  • 1. miR-181d-5p ameliorates hypercholesterolemia by targeting PCSK9.
    Wang Y; Li F; Gao X; Yu H; Du Z; Li L; Du Y; Hu C; Qin Y
    J Endocrinol; 2024 Sep; 262(3):. PubMed ID: 38940622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production.
    Dong J; He M; Li J; Pessentheiner A; Wang C; Zhang J; Sun Y; Wang WT; Zhang Y; Liu J; Wang SC; Huang PH; Gordts PL; Yuan ZY; Tsimikas S; Shyy JY
    JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33119548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice.
    Xu X; Dong Y; Ma N; Kong W; Yu C; Gong L; Chen J; Ren J
    Metabolism; 2021 Jun; 119():154768. PubMed ID: 33775647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors.
    Levstek T; Karun T; Rehberger Likozar A; Šebeštjen M; Trebušak Podkrajšek K
    Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.
    Lu H; Howatt DA; Balakrishnan A; Graham MJ; Mullick AE; Daugherty A
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1753-7. PubMed ID: 27470509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid Lowering Therapy and Circulating PCSK9 Concentration.
    Nozue T
    J Atheroscler Thromb; 2017 Sep; 24(9):895-907. PubMed ID: 28804094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model.
    Carreras A; Pane LS; Nitsch R; Madeyski-Bengtson K; Porritt M; Akcakaya P; Taheri-Ghahfarokhi A; Ericson E; Bjursell M; Perez-Alcazar M; Seeliger F; Althage M; Knöll R; Hicks R; Mayr LM; Perkins R; Lindén D; Borén J; Bohlooly-Y M; Maresca M
    BMC Biol; 2019 Jan; 17(1):4. PubMed ID: 30646909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
    Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
    J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Loss-of-Function Mutations in PCSK9 Reduce Plasma LDL Cholesterol.
    Meng FH; Liu S; Xiao J; Zhou YX; Dong LW; Li YF; Zhang YQ; Li WH; Wang JQ; Wang Y; Song BL; Ma YT; Fu ZY; Luo J
    Arterioscler Thromb Vasc Biol; 2023 Jul; 43(7):1219-1233. PubMed ID: 37165876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
    Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artificial Platelets for Efficient siRNA Delivery to Clear "Bad Cholesterol".
    Zhang Y; Qin Y; Li H; Peng Q; Wang P; Yang L; Chen S; Li M; Fu J; Yu X; Zhang L
    ACS Appl Mater Interfaces; 2020 Jun; 12(25):28034-28046. PubMed ID: 32469502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
    Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
    Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hsa-miR-140-5p down-regulates LDL receptor and attenuates LDL-C uptake in human hepatocytes.
    Xu Y; Gao J; Gong Y; Chen M; Chen J; Zhao W; Tan S
    Atherosclerosis; 2020 Mar; 297():111-119. PubMed ID: 32109664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression.
    Tao R; Xiong X; DePinho RA; Deng CX; Dong XC
    J Biol Chem; 2013 Oct; 288(41):29252-9. PubMed ID: 23974119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE
    Gu L; Gong Y; Zhao C; Wang Y; Tian Q; Lei G; Liang Y; Zhao W; Tan S
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31731717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting PCSK9 for the treatment of hypercholesterolemia.
    Hedrick JA
    Curr Opin Investig Drugs; 2009 Sep; 10(9):938-46. PubMed ID: 19705336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.